• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
microRNA-494 is a potential prognostic marker and inhibits cellular proliferation, migration and invasion by targeting SIRT1 in epithelial ovarian cancer.微小RNA-494是一种潜在的预后标志物,通过靶向沉默信息调节因子1(SIRT1)抑制上皮性卵巢癌的细胞增殖、迁移和侵袭。
Oncol Lett. 2017 Sep;14(3):3177-3184. doi: 10.3892/ol.2017.6501. Epub 2017 Jun 30.
2
MicroRNA‑455 inhibits cell proliferation and invasion of epithelial ovarian cancer by directly targeting Notch1.微小 RNA-455 通过直接靶向 Notch1 抑制上皮性卵巢癌的细胞增殖和侵袭。
Mol Med Rep. 2017 Dec;16(6):9777-9785. doi: 10.3892/mmr.2017.7790. Epub 2017 Oct 13.
3
Inhibition of Ovarian Epithelial Carcinoma Tumorigenesis and Progression by microRNA 106b Mediated through the RhoC Pathway.微小RNA 106b通过RhoC途径介导抑制卵巢上皮癌的肿瘤发生和进展
PLoS One. 2015 May 1;10(5):e0125714. doi: 10.1371/journal.pone.0125714. eCollection 2015.
4
MicroRNA-137 suppresses tumor growth in epithelial ovarian cancer in vitro and in vivo.微小RNA-137在体外和体内均可抑制上皮性卵巢癌的肿瘤生长。
Mol Med Rep. 2015 Aug;12(2):3107-14. doi: 10.3892/mmr.2015.3756. Epub 2015 May 7.
5
MicroRNA-130b functions as a tumor suppressor by regulating RUNX3 in epithelial ovarian cancer.微小RNA-130b通过调控上皮性卵巢癌中的RUNX3发挥肿瘤抑制作用。
Gene. 2016 Jul 15;586(1):48-55. doi: 10.1016/j.gene.2016.04.001. Epub 2016 Apr 2.
6
miRNA-574-3p inhibits metastasis and chemoresistance of epithelial ovarian cancer (EOC) by negatively regulating epidermal growth factor receptor (EGFR).微小RNA-574-3p通过负向调节表皮生长因子受体(EGFR)来抑制上皮性卵巢癌(EOC)的转移和化疗耐药性。
Am J Transl Res. 2019 Jul 15;11(7):4151-4165. eCollection 2019.
7
MiR-143 targets CTGF and exerts tumor-suppressing functions in epithelial ovarian cancer.微小RNA-143靶向结缔组织生长因子并在上皮性卵巢癌中发挥肿瘤抑制功能。
Am J Transl Res. 2016 Jun 15;8(6):2716-26. eCollection 2016.
8
S100A7 Regulates Ovarian Cancer Cell Metastasis and Chemoresistance Through MAPK Signaling and Is Targeted by miR-330-5p.S100A7 通过 MAPK 信号调节卵巢癌细胞转移和化疗耐药性,并且受 miR-330-5p 靶向调控。
DNA Cell Biol. 2018 May;37(5):491-500. doi: 10.1089/dna.2017.3953. Epub 2018 Feb 27.
9
DPY30 is required for the enhanced proliferation, motility and epithelial-mesenchymal transition of epithelial ovarian cancer cells.DPY30 对于增强上皮性卵巢癌细胞的增殖、迁移和上皮-间充质转化是必需的。
Int J Mol Med. 2018 Dec;42(6):3065-3072. doi: 10.3892/ijmm.2018.3869. Epub 2018 Sep 11.
10
MicroRNA-320a Promotes Epithelial Ovarian Cancer Cell Proliferation and Invasion by Targeting RASSF8.微小RNA-320a通过靶向RASSF8促进上皮性卵巢癌细胞的增殖和侵袭。
Front Oncol. 2021 Feb 25;11:581932. doi: 10.3389/fonc.2021.581932. eCollection 2021.

引用本文的文献

1
Exploring microRNA targeting as a promising approach for solid tumor treatment.探索将微小RNA靶向作为实体瘤治疗的一种有前景的方法。
Front Oncol. 2025 Jul 21;15:1570093. doi: 10.3389/fonc.2025.1570093. eCollection 2025.
2
Utilization of miRNAs as Biomarkers for the Diagnosis, Prognosis, and Metastasis in Gynecological Malignancies.利用 miRNA 作为妇科恶性肿瘤诊断、预后和转移的生物标志物。
Int J Mol Sci. 2024 Oct 31;25(21):11703. doi: 10.3390/ijms252111703.
3
Current strategies for early epithelial ovarian cancer detection using miRNA as a potential tool.使用微小RNA(miRNA)作为潜在工具进行早期上皮性卵巢癌检测的当前策略。
Front Mol Biosci. 2024 Apr 16;11:1361601. doi: 10.3389/fmolb.2024.1361601. eCollection 2024.
4
MicroRNA targeting: A novel therapeutic intervention for ovarian cancer.微小RNA靶向作用:卵巢癌的一种新型治疗干预手段
Biochem Biophys Rep. 2023 Jul 24;35:101519. doi: 10.1016/j.bbrep.2023.101519. eCollection 2023 Sep.
5
Modulation of AKT Pathway-Targeting miRNAs for Cancer Cell Treatment with Natural Products.天然产物对 AKT 通路靶向 miRNA 的调控在癌症细胞治疗中的作用。
Int J Mol Sci. 2023 Feb 12;24(4):3688. doi: 10.3390/ijms24043688.
6
Extracellular Vesicles-ceRNAs as Ovarian Cancer Biomarkers: Looking into circRNA-miRNA-mRNA Code.作为卵巢癌生物标志物的细胞外囊泡-ceRNAs:探究环状RNA-微小RNA-信使RNA编码
Cancers (Basel). 2022 Jul 13;14(14):3404. doi: 10.3390/cancers14143404.
7
Role of different non-coding RNAs as ovarian cancer biomarkers.不同非编码 RNA 作为卵巢癌生物标志物的作用。
J Ovarian Res. 2022 Jun 17;15(1):72. doi: 10.1186/s13048-022-01002-3.
8
Identification of keygenes, miRNAs and miRNA-mRNA regulatory pathways for chemotherapy resistance in ovarian cancer.卵巢癌化疗耐药关键基因、miRNA及miRNA-mRNA调控通路的鉴定
PeerJ. 2021 Nov 8;9:e12353. doi: 10.7717/peerj.12353. eCollection 2021.
9
SIRT1 and gynecological malignancies (Review).SIRT1 与妇科恶性肿瘤(综述)。
Oncol Rep. 2021 Apr;45(4). doi: 10.3892/or.2021.7994. Epub 2021 Mar 2.
10
The Role of microRNAs in Epithelial Ovarian Cancer Metastasis.微小 RNA 在卵巢上皮性癌转移中的作用。
Int J Mol Sci. 2020 Sep 25;21(19):7093. doi: 10.3390/ijms21197093.

本文引用的文献

1
Overexpression of SIRT1 is Associated With Poor Outcomes in Patients With Ovarian Carcinoma.SIRT1过表达与卵巢癌患者的不良预后相关。
Appl Immunohistochem Mol Morphol. 2017 Jul;25(6):415-421. doi: 10.1097/PAI.0000000000000316.
2
MicroRNA-494 inhibits cell proliferation and invasion of chondrosarcoma cells in vivo and in vitro by directly targeting SOX9.微小RNA-494通过直接靶向SOX9在体内和体外抑制软骨肉瘤细胞的增殖和侵袭。
Oncotarget. 2015 Sep 22;6(28):26216-29. doi: 10.18632/oncotarget.4460.
3
MicroRNAs in Ovarian Cancer.卵巢癌中的微小RNA
Hum Pathol. 2015 Sep;46(9):1245-56. doi: 10.1016/j.humpath.2015.06.013. Epub 2015 Jun 30.
4
Increased expression of microRNA-196a predicts poor prognosis in human ovarian carcinoma.微小RNA-196a表达增加预示着人类卵巢癌预后不良。
Int J Clin Exp Pathol. 2015 Apr 1;8(4):4132-7. eCollection 2015.
5
miR-494 promotes cell proliferation, migration and invasion, and increased sorafenib resistance in hepatocellular carcinoma by targeting PTEN.微小RNA-494通过靶向磷脂酰肌醇-3-激酶的磷酸酶和张力蛋白同源物促进肝细胞癌的细胞增殖、迁移和侵袭,并增强对索拉非尼的耐药性。
Oncol Rep. 2015 Aug;34(2):1003-10. doi: 10.3892/or.2015.4030. Epub 2015 Jun 4.
6
MicroRNA-204 inhibits proliferation, migration, invasion and epithelial-mesenchymal transition in osteosarcoma cells via targeting Sirtuin 1.微小RNA-204通过靶向沉默调节蛋白1抑制骨肉瘤细胞的增殖、迁移、侵袭及上皮-间质转化。
Oncol Rep. 2015 Jul;34(1):399-406. doi: 10.3892/or.2015.3986. Epub 2015 May 19.
7
Ectopic expression of miR-494 inhibited the proliferation, invasion and chemoresistance of pancreatic cancer by regulating SIRT1 and c-Myc.miR-494 的异位表达通过调节 SIRT1 和 c-Myc 抑制了胰腺癌的增殖、侵袭和化疗耐药性。
Gene Ther. 2015 Sep;22(9):729-38. doi: 10.1038/gt.2015.39. Epub 2015 Apr 28.
8
miR-494 suppresses the progression of breast cancer in vitro by targeting CXCR4 through the Wnt/β-catenin signaling pathway.微小RNA-494通过Wnt/β-连环蛋白信号通路靶向趋化因子受体4,在体外抑制乳腺癌进展。
Oncol Rep. 2015 Jul;34(1):525-31. doi: 10.3892/or.2015.3965. Epub 2015 May 8.
9
Decreased expression of microRNA-124 is an independent unfavorable prognostic factor for patients with breast cancer.微小RNA-124表达降低是乳腺癌患者独立的不良预后因素。
Diagn Pathol. 2015 Apr 29;10:45. doi: 10.1186/s13000-015-0257-5.
10
The clinicopathological significance of miR-1307 in chemotherapy resistant epithelial ovarian cancer.miR-1307在化疗耐药上皮性卵巢癌中的临床病理意义
J Ovarian Res. 2015 Apr 9;8:23. doi: 10.1186/s13048-015-0143-5.

微小RNA-494是一种潜在的预后标志物,通过靶向沉默信息调节因子1(SIRT1)抑制上皮性卵巢癌的细胞增殖、迁移和侵袭。

microRNA-494 is a potential prognostic marker and inhibits cellular proliferation, migration and invasion by targeting SIRT1 in epithelial ovarian cancer.

作者信息

Yang Aijun, Wang Xuenan, Yu Chunna, Jin Zhenzhen, Wei Lingxia, Cao Jinghe, Wang Qin, Zhang Min, Zhang Lin, Zhang Lei, Hao Cuifang

机构信息

Center for Reproductive Medicine, Affiliated Hospital of Jining Medical University, Jining, Shandong 272029, P.R. China.

Department of Clinical Medicine, Jining Medical University, Jining, Shandong 272067, P.R. China.

出版信息

Oncol Lett. 2017 Sep;14(3):3177-3184. doi: 10.3892/ol.2017.6501. Epub 2017 Jun 30.

DOI:10.3892/ol.2017.6501
PMID:28927063
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5588040/
Abstract

Ovarian cancer is one of the most common types of gynecological malignancy worldwide, and is the fourth leading cause of cancer-associated mortality among women. Despite improvements in therapeutic treatments, the prognosis for epithelial ovarian cancer (EOC) remains poor, mainly due to the rapid growth and metastasis of ovarian cancer tumors. An increasing number of studies have indicated that microRNAs (miRNAs) are involved in the carcinogenesis and progression of human cancer, suggesting that miRNAs may be used in clinical prognosis and as a therapeutic target in EOC. The aim of the present study was to investigate the expression levels of miRNA-494 in EOC tissues and cell lines. The clinical significance of miRNA-494 in patients with EOC was also evaluated. The results demonstrated that miRNA-494 was significantly downregulated in EOC tissues and cell lines. Low expression levels of miRNA-494 were associated with poor prognostic features, including International Federation of Gynecology and Obstetrics stage, tumor size and lymph node metastasis. functional studies demonstrated that overexpression of miRNA-494 inhibited proliferation, migration and invasion in EOC cells. By contrast, knockdown of miRNA-494 enhanced cell growth, migration and invasion in EOC cells. Notably, sirtuin 1 (SIRT1) was identified as a direct target of miRNA-494 in EOC. Furthermore, MTT, cell migration and invasion assays verified that EOC cell proliferation, migration and invasion were completely restored with forced miRNA-494 expression and SIRT1 restoration. Together, these findings suggest that miRNA-494 is a potential prognostic marker, and may provide novel therapeutic regimens of targeted therapy for EOC.

摘要

卵巢癌是全球最常见的妇科恶性肿瘤类型之一,也是女性癌症相关死亡的第四大主要原因。尽管治疗方法有所改进,但上皮性卵巢癌(EOC)的预后仍然很差,主要是由于卵巢癌肿瘤的快速生长和转移。越来越多的研究表明,微小RNA(miRNA)参与人类癌症的发生和发展,这表明miRNA可用于临床预后评估,并作为EOC的治疗靶点。本研究的目的是调查miRNA-494在EOC组织和细胞系中的表达水平。还评估了miRNA-494在EOC患者中的临床意义。结果表明,miRNA-494在EOC组织和细胞系中显著下调。miRNA-494的低表达水平与不良预后特征相关,包括国际妇产科联盟分期、肿瘤大小和淋巴结转移。功能研究表明,miRNA-494的过表达抑制了EOC细胞的增殖、迁移和侵袭。相反,敲低miRNA-494可增强EOC细胞的生长、迁移和侵袭。值得注意的是,沉默调节蛋白1(SIRT1)被确定为EOC中miRNA-494的直接靶点。此外,MTT、细胞迁移和侵袭试验证实,通过强制表达miRNA-494和恢复SIRT1,EOC细胞的增殖、迁移和侵袭完全恢复。总之,这些发现表明miRNA-494是一种潜在的预后标志物,并可能为EOC提供新的靶向治疗方案。